These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21916809)

  • 1. Clinical and investigational use of proteasome inhibitors for transplant rejection.
    Sadaka B; Alloway RR; Woodle ES
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1535-42. PubMed ID: 21916809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitor therapy for antibody-mediated rejection.
    Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
    Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-mediated rejection in kidney transplantation: an update.
    Lucas JG; Co JP; Nwaogwugwu UT; Dosani I; Sureshkumar KK
    Expert Opin Pharmacother; 2011 Mar; 12(4):579-92. PubMed ID: 21294653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition for antibody-mediated allograft rejection.
    Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitor-based therapy for antibody-mediated rejection.
    Walsh RC; Alloway RR; Girnita AL; Woodle ES
    Kidney Int; 2012 Jun; 81(11):1067-74. PubMed ID: 22336990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
    Ejaz NS; Alloway RR; Halleck F; Dürr M; Budde K; Woodle ES
    Antioxid Redox Signal; 2014 Dec; 21(17):2401-18. PubMed ID: 24635140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition for antibody-mediated rejection.
    Everly JJ; Walsh RC; Alloway RR; Woodle ES
    Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
    Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
    Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
    Claes DJ; Yin H; Goebel J
    Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
    Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
    Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.
    Ryckewaert A; Allain-Launay E; Moreau A; Blancho G; Cesbron A; Blin N; Roussey G
    Pediatr Transplant; 2013 Sep; 17(6):E131-6. PubMed ID: 23834525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib for refractory antibody-mediated cardiac allograft rejection.
    Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES
    Clin Transpl; 2009; ():475-8. PubMed ID: 20524318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition reduces donor-specific antibody levels.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
    Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.